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The current SARS-COV2 virus (COVID-19) pandemic has
placed significant stress on healthcare systems and hospitals
around the globe. Following the initial outbreak in China, several
countries in Europe (Italy, UK, Spain, France), as well as the
United States have been among those most severely impacted.
Some countries in Europe, like Switzerland, had time to anticipate
and prepare so as to avoid the dramatic situations that occurred in
Northern Italy in March, as well as in New York in April. While
operating room volume was impacted in many centers, the extent
of advance preparation varied. For example, in many institutions,
operating room volume was decreased by 60% or more and
operating rooms and recovery areas were converted to intensive
care beds. This led to a dramatic increase in intensive care unit
(ICU) capacity and in the number of health care professionals
allocated to the ICU. The response to the COVID-19 pandemic
has had significant implications on the surgical management of
hepatobiliary diseases that has been accompanied by high levels of
uncertainty and lack of uniformity as institutions have had
to respond quickly with rapid implementation of policies based
on the available data at that time.
While COVID-19 is not known to cause specific symptoms in
the liver, pancreas or biliary tract, the pandemic have resulted in
significant implications for the delivery of surgery related to
hepato-pancreato-biliary (HPB) disorders. Decision-makingHPB 2020, 22, 1135–1138 © 2020 International Hepato-Pbased on the risks and benefits of an operation, as well as who
to offer, has become much more complex during the current
pandemic. In order to conserve hospital resources and reduce
nosocomial transmission of the virus, many jurisdictions and
hospitals have placed significant constraints on surgical activity.
The decisions on how to limit surgical procedures during a
public health crisis such as the COVID-19 pandemic should be
made based on a variety of disease and local hospital and system
factors (Table 1). These factors include the severity of the illness,
the ability to diagnose COVID-affected persons or carriers, and
the impact on hospital and healthcare resources. The symptoms
of COVID-19 infection can range from asymptomatic carrier, to
respiratory failure requiring ventilatory support. During the
exponential growth phase of viral infection, most hospitals and
health systems have taken the step of reducing or cancelling
elective surgery. While definitions of “elective” surgery may vary,
such operations are generally considered to be surgical proced-
ures where delay of the intervention is possible without patient
harm.
The decisions to proceed with operations for “semi-urgent”
procedures vary significantly by the local COVID infection rates
and the available hospital resources. The threshold used in
defining “semi-urgent” surgery will depend on the length of time
of which deferral or delay of surgery is thought to be safe. These
decisions must often be made on a case-by-case decision;
surgeons should consider safe alternatives to surgery that can be
used to increase the safety of surgical delay. For example, stenting
of biliary or gastrointestinal obstruction as well as initiation or
continuation of neoadjuvant therapy for cancers should beancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Table 1 Factors to consider in Allocating Surgical Resources in a
Pandemic
Virus Factors
- Mode of Transmission
- Virulence
- Local Prevalence
- Availability and Accuracy of diagnosis/testing
Local Health System Factors
- Institutional supply of Personal Protective Equipment (PPE)
- Institutional resources- surgical supplies, inpatient beds, ICU
resources
- Local/national government regulations
1136 HPBconsidered (Table 2). If a dramatic increase in COVID-patients
with a concomitant decrease in OR capacity is anticipated, a
plan should be developed to modify the treatment strategy of
patients while minimizing the risks of delayed operative inter-
vention. In particular, three strategies have been employed as a
means to decrease surgical volumes:
1) delay the operation: e.g. by giving chemotherapy for a
prolonged period, allowing a slightly longer prolongation
time to surgery
2) modify the treatment strategy: e.g. neoadjuvant treatment in
resectable pancreas cancer has not been adopted widely yet.
Thus, it was proposed to give neoadjuvant chemotherapy
routinely prior to pancreas resection, with expanded
indications.
3) change strategy: instead of immediate operation, choose
another non-surgical option with similar expected outcomes
(e.g. for small hepatocellular carcinoma (HCC) consider
radio-embolization (SIRT) rather than resection).
In addition, as one considers how to treat HPB surgical patients
during this pandemic, one should account for the risk of COVIDTable 2 Common definitions of urgency for surgical procedures
Urgent/Emergency Surgery
- Unstable condition requiring immediate care.
- Risk of medical harm if care is delayed
- Delay in care is likely to increase mortality and morbidity.
Semi-Urgent Surgery
- Active, stable medical issues with potential of progression to urgent
with prolonged deferral
- Significant delay will result in progression to local unresectability or
requiring escalation of procedure with increased morbidity/
mortality.
- Significant delay will likely lead to meaningful change in care plan.
- Hospitalized patients where the operation or procedure would
provide opportunity for discharge
- Need for palliation unresponsive to maximal medical management.
Elective Surgery
- Stable surgical issues not meeting Urgent or Semi Urgent criteria
- Non-essential procedures that can be delayed without undue risk to
the patients health
- Surgical problems with well-established, adequate local care.
HPB 2020, 22, 1135–1138 © 2020 International Hepato-Pinfection amongst surgeons and surgical team members, and
assess the resources in the loco-regional healthcare system. In these
unprecedented times, there are obvious limitations within hospi-
tals that must be considered before embarking on an operation
that utilizes physician and nursing teams, other staff, an operating
room, a ventilator, and a hospital bed. Some of these operations
may also necessitate an ICU bed postoperatively. Furthermore,
there is the issue of exposure –from hospital staff to patient,
patient to staff, and also patient to patient. Anticipating peaks of
COVID-related disease and resource utilization, as well as duration
of resource utilization, are important and must be considered in
the context of patients presenting with malignancies.
HPB malignancies, in general, are aggressive cancers. Specif-
ically, pancreatic adenocarcinoma, cholangiocarcinoma, gall-
bladder adenocarcinoma, primary liver malignancies and liver
metastases are all malignancies that generally progress off treat-
ment. Many patients with these diseases, if left untreated, have a
median survival of less than a year. Importantly, delay in surgical
treatment may allow these cancers to progress and become unre-
sectable. The Society of Surgical Oncology has recommended that
surgeons should “ …. operate on all patients with aggressive HPB
malignancies as indicated.” There are some strategies, including
intra-arterial hepatic therapies and chemotherapy among others,
that can serve to delay surgery and extend the duration of time
resectability can be maintained. While the ultimate decision must
depend on the availability of resources, these cancers can be lethal,
and attempts at safe and expeditious surgery should be prioritized.
Indeed, the American College of Surgeons Elective Surgery Acuity
Scale considers most cancers to reside within Tier 3a for which no
postponements are recommended (https://www.facs.org/about-
acs/covid-19/information-for-surgeons/triage).
There has also been a significant decline in the number of liver
transplants performed in the US since the week of March 2nd
2020 (https://unos.org/covid/) (Fig. 1). The reason for this
decrease is undoubtedly multifactorial and likely depends on the
prevalence of the virus with some centers only transplanting
extremely sick transplant patients due to health resource limi-
tations. There has also been a steep drop in cadaveric donation
(https://unos.org/covid/). The decrease may be due to decreased
consent related to family fear of extra time in the hospital,
absence of family in the hospital preventing face-to-face in-
teractions with Organ Procurement Organization personnel to
aid in the donation process for families. In addition, due to the
states quarantine rules, a marked decrease in motor vehicle
collisions and violent crimes has led to fewer potential donors.
Most centers also have halted or severely cut back on living donor
liver transplants and some recipients are refusing to come for
transplant as they fear the risk of infection from COVID-19 is
too high. Recommendations from the American Society of
transplant surgeons (ASTS) Task Force can be found at:
https://asts.org/advocacy/covid-19-resources/asts-covid-19-
strike-force/asts-covid-19-strike-force-initial-guidance#.
Xpytm9NKjUI (Table 3).ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Figure 1 Pre-operative COVID-19 Screening protocol
Table 3 Recommendations from the American Society of transplant
surgeons (ASTS) Task Force
 Lifesaving and life altering transplants should continue to be
performed.
 Living donations (assuming the recipient can wait) should be placed
hold until the course of the US penetrance of COVID-19 is
understood.
 Deceased donor transplants must be undertaken cautiously and
considered on a case-by-case basis. Consideration includes
whether the facility has the current and future capacity to provide
adequate post-operative care. Considerations should be given to
availability of beds and adequate blood component supply
 The transplant team must evaluate each organ offer for the specific
potential recipient in light of resource availability and total course,
prior to deciding whether to proceed with transplant.
 Informed consent processes and protocols should be assessed, so
that recipients and families understand the risks and benefits during
this uncertain time.
 Induction immunosuppression places an organ recipient in a
vulnerable state for many months andmay jeopardize the survival or
post-transplant care if the recipient contracts the virus. There is a
paucity of data, however, for safety we recommend limited use of
induction therapy during this COVID-19 surge. - Lymphocyte
depletion should be used with great caution.
 Consideration must also include where and with whom
convalescence will occur.
o Centers must factor what will happen if the patient or caregiver
becomes exposed/infected with COVID-19?
o Is there the capacity to quarantine, monitor and treat the recipient
or caregiver?
 Transplantation is not just the surgical procedure; it can include a
protracted treatment that will likely be impacted by pandemic.
 It is possible that sick healthcare professionals will take care of sick
patients.
Derived from. ASTS task force site: https://asts.org/advocacy/covid-19-
resources/asts-covid-19-strike-force/asts-covid-19-strike-force-initial-
guidance#.Xpytm9NKjUI.
HPB 1137UNOS recommends centers asked that organ recovery be
performed by local transplant center surgeons to minimize out of
town teams travelling and mixing of multiple teams at various
donor hospital sites. While donors are now all being universally
tested for COVID-19, recipient testing is more variable
depending on center availability and demand; when done,
recipient testing should be done on admission to the hospital,
and ideally have a result pre-transplant; if the test is not back at
the time of transplant, this information can be used to manage
immunosuppression in the post-operative period should the test
come back positive.
The availability of testing (both serology and direct viral
testing) is critical to decisions around surgery. As we all develop
protective strategies and wait for the more ubiquitous availability
of testing, it is becoming obvious that routine testing of patients
and hospital staff will become critically important. For patients
where it is deemed appropriate to proceed with surgery, testing
should take place to determine the COVID status or the risk of
infection of each patient. Screening questions can be used to
determine the likelihood of exposure or infection including: travel
history to high prevalence areas; exposure to people suspected to
be COVID positive or under quarantine; fever >38 C; new res-
piratory symptoms (cough, shortness of breath, sore throat); or
diarrhea. In some instances, patients are being asked to self-
quarantine six days prior to their procedure. In addition, an
increasing number of centers are implementing testing for
COVID-19 RNA via PCR two days prior to surgery (Fig. 1). If the
test is equivocal or if suspicion of COVID-19 positivity is high, a
CT chest has been used as an additional screening tool with
ground-glass opacities a possible early indicator of disease. Pa-
tients that are COVID-19 PCR negative proceed to surgery.
During induction and intubation, all non-anesthesia personnel
should consider distancing themselves or leave the operating
room while the anesthesia team maintain aerosol and droplet
precautions including N95 masks and splashguards. Following
intubation, anesthesia remain in the room and droplet pre-
cautions are maintained for up to 20–30 min, which represents
seven replacement/recirculation times of the air in the operating
theatre. As such, in many centers the operative team only returns
to the operating room after this time has passed such that theHPB 2020, 22, 1135–1138 © 2020 International Hepato-Pprocedure can proceed. Droplet/Aerosol precautions (N95
masks) are maintained throughout the case by all OR personnel
for aerosol generating procedures (AGPs) such as airway pro-
cedures, endoscopy/bronchoscopy and oral-maxillofacial
procedures. Whether laparoscopy or robotic surgery should be
considered an increased risk of COVID-19 dissemination remains
debatable. At the conclusion of the operation, similar procedures
are observed for extubation with aerosol/droplet precautions
being observed by anesthesia team members while other staffancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
1138 HPBleave the room. The patient should be recovered in the operating
room for 21–30 min before transfer to the recovery area. For
patients who are found to be COVID-19 PCR positive on pre-
operative screening, and where delay can reasonably be consid-
ered, surgery is deferred at least two weeks. After a 2 week
deferral, the patient’s symptoms are reassessed. If the patient is
asymptomatic they are retested and if found to be COVID-19
PCR negative they can then proceed to surgery under the usual
precautions. If at any time a COVID-19 positive patient cannot be
deferred due to risk or progression of disease, the surgery may be
allowed to proceed under aerosol/droplet precautions.
Testing of providers also remains variable and has not been
universally feasible. Of note, in some places, in addition to all
surgical patients being tested in order to allow protective mea-
sure for the OR team, only symptomatic health care workers are
tested. In Lausanne, among over 1700 tested health care workers,
the COVID positive rate was about 17%, making the overall
COVID positive rate of 1.6% for the entire health care workers
working in at the academic tertiary center in Lausanne, thus
demonstrating that protective measures were efficient. These
data are important given that in Italy over 100 physicians have
died from Covid-19. The limitations of testing resources are
compounded by a potential lack of sensitivity. The most
common and earliest available test, COVID RNA-PCR, may not
become positive for 3–5 days after exposure.
The change in numbers and types of admitted patients and
operative cases due to COVID19, as well as related changes in
workflow, service assignments and hands-on teaching, are
significantly impacting trainees at every level. The impact on




trainingreq) to fellow (https://acgme.org/COVID-19/Three-
Stages-of-GME-During-the-COVID-19-Pandemic & https://
twitter.com/FellowshpCouncl/status/1239932992400658433),
and the effects of the pandemic are likely to persist for trainees for
several years to come. In particular, at the resident and fellow
level, HPB operations for benign and malignant disease may be
canceled or limited. The duration and extent of cancellation has
varied across the US, with some institutions so overwhelmed with
COVID that no non-urgent operations are being undertaken and
with near-regular volume at other centers. Decisions to cancel or
modify operations have been impacted by the volume of COVID,
availability of ICU beds and PPE, policies on the use of MIS
techniques, and redeployment of surgeons to other teams and
services during this time. Changes in OR scheduling began in
early March in some parts of the US and may extend still for
months to come. Senior residents may thus lose their anticipated
advanced experiences in HPB surgery that were intended to
optimize their preparation for fellowship. Fellows may be missing
out on expected increased independence intended to facilitateHPB 2020, 22, 1135–1138 © 2020 International Hepato-Ptheir upcoming transition to attending or faculty surgery posi-
tion. Non-operative training has also been affected by the
pandemic, as many clinics have transitioned to tele-medicine and/
or canceled non-urgent visits, and even multidisciplinary clinics
may be virtual. As surgeons by and large are new to telemedicine,
trainees have had no formal training in this approach; in turn,
telemedicine training will need to be developed.
In-patient care has also been impacted in many institutions, in
order to allow for coverage of COVID-related services such as
emergency general surgery, vascular access, and ICU. Further-
more, in advance of the anticipated COVID surge, training
programs may have adjusted work schedules. One common
approach has been to assign one or two-week blocks of on-duty,
followed by time of “work from home”, in order to limit expo-
sure risk by limiting time in the hospital when feasible. In some
institutions, the usual subspecialty services combined to a team
of fewer residents and fewer attending surgeons at a time as non-
urgent cases were delayed. In some places, residents and fellows
have been redeployed to departments and services outside their
normal areas, which of course necessarily changes their focus for
this period of time and disrupts expected educational experi-
ences. Residents have been assigned to restructured services in
general surgery, surgical consults, and ICU primarily, keeping
them within the Department of Surgery. Fellows have also been
eligible for assignment based on their level of training and area of
subspecialty training. Given that in some cases, attending sur-
geons have been reassigned to other areas, trainees may be su-
pervised by surgeons other than their usual supervising attending
surgeons. It is critical to ensure that appropriate supervision is
readily available during this time.
Most training programs in surgery and surgical subspecialties
have seen changes in the mode of delivery of didactics as well as
other conferences during this time. In most instances, weekly
residency-wide teaching sessions have continued but is now
virtual. Several services have now created regular resident and
fellow-level virtual teaching sessions, including, for example,
journal club, preoperative conference, literature or topical
review. Many departments are conducting grand rounds lectures
and/or Morbidity & Mortality conferences virtually as well. In
general, virtual conferences have been well-received by both
trainees and faculty. The next step includes adaptation of tech-
nical skills training to a virtual setting. This effort is already
underway in some programs, and will further develop. However,
the larger society conferences have been canceled, causing the
loss of associated opportunities to trainees, who normally would
attend such meetings for learning opportunities, to present
research, and to network for job and academic opportunities.
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